Viatris (VTRS) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has approved Effexor SR 37.5 mg / 75 mg capsules, a serotonin-noradrenaline reuptake inhibitor, for the treatment of adults with generalized anxiety disorder. Following the MHLW’s decision, Effexor becomes the first and only approved treatment option in Japan for adults living with GAD. Effexor is currently approved in Japan for the indication of major depressive disorder in adults, and with this approval, is now available to patients with GAD.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTRS:
- Viatris outlines vision for growth through 2030
- Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
- Unusually active option classes on open March 12th
- The Week That Was, The Week Ahead: Macro and Markets, Mar. 8
- Viatris Earnings Call Highlights Slow Growth, Cash Strength